Cargando…
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient populati...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/ https://www.ncbi.nlm.nih.gov/pubmed/28331612 http://dx.doi.org/10.1186/s40364-017-0093-8 |